Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of r
about
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysisHMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysisReducing the costs of chronic kidney disease while delivering quality health care: a call to action.Prevalence and risk factors of microalbuminuria in Thai nondiabetic hypertensive patients.Chronic kidney disease and end-stage renal disease-a review produced to contribute to the report 'the status of health in the European union: towards a healthier Europe'.World kidney day 2011: protect your kidneys, save your heart.Cost-effectiveness of angiotensin-converting enzyme inhibitors for the prevention of diabetic nephropathy in The Netherlands--a Markov model.Population based screening for chronic kidney disease: cost effectiveness study.Albuminuria: Prevalence, associated risk factors and relationship with cardiovascular disease.Microalbuminuria screening for detecting chronic kidney disease in the general population: a systematic review.Screening for albuminuria identifies individuals at increased renal riskAssociation of microalbuminuria with ischemic heart disease in non-diabetic Asian-Indians: A case control study.A population-based survey of Chronic REnal Disease In Turkey--the CREDIT study.Cost-effectiveness analysis of a randomized trial comparing care models for chronic kidney diseaseThe total urine protein-to-creatinine ratio can predict the presence of microalbuminuriaWorld Kidney Day 2011 - Protect your kidneys, save your heart.Urinary albumin-creatinine ratio, estimated glomerular filtration rate, and all-cause mortality among US adults with obstructive lung function.Maintenance Dialysis throughout the World in Years 1990 and 2010.Validation of an Albuminuria Self-assessment Tool in the Multi-Ethnic Study of AtherosclerosisUrinary albumin excretion and the renin-angiotensin system in cardiovascular risk management.Microalbuminuria: what is it? Why is it important? What should be done about it? An update.Prevalence of Early Stages of Chronic Kidney Disease in Healthy Army PersonnelHypertension in pregnancy is a risk factor for microalbuminuria later in life.Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands.Proteinuria and its relation to cardiovascular disease.Economic evaluations of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in type 2 diabetic nephropathy: a systematic review.Statins in patients with chronic kidney disease: why, who and when?Early detection of CKD: the benefits, limitations and effects on prognosis.Microcirculation on a large scale: techniques, tactics and relevance of studying the microcirculation in larger population samples.Screening for elevated albuminuria and subsequently hypertension identifies subjects in which treatment may be warranted to prevent renal function decline.To screen or not to screen: that is not (yet) the question.A call to action on World Kidney Day, 8 March 2007.Handling Missing Data in Within-Trial Cost-Effectiveness Analysis: A Review with Future Recommendations.Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD).
P2860
Q24194514-EE729F1E-BCF3-4041-B4FE-3A380758EFAEQ24241472-7E478208-DC73-4665-A688-511A876050FFQ30234324-2B1A4BB8-892D-4B1F-80F8-B6E7D6E7CE50Q33813773-4A206272-F5B3-4211-974D-29882759E8F2Q33816875-40762AAE-72E2-40DE-A16B-0B7A5108A00BQ33871733-41D1DA45-0CDF-49C3-996B-CCAB9B1BC854Q34056044-DAD137FD-7696-46BE-B771-4AB106EADFE7Q34286311-48B55341-B006-41A7-97E2-222E128D31B5Q34407904-0BBDA672-3AB1-4170-960A-C202C66A79AFQ34638312-D882B720-166C-4E1E-A340-6DC78876E0C5Q34658059-B8A54141-DCD3-4B24-AA39-FF214B5237E7Q34975515-65573AF4-5643-4684-8133-5D0BB4BC361CQ35023531-70235668-499A-46F9-91F5-AAB13C730523Q35030546-841FA877-6F10-4669-9910-49E8F8214621Q35116286-DB1F63A5-6857-423C-A066-19C27F9F1423Q35673984-9CFDBC00-1A6B-4157-967F-954394ACD045Q36087862-0365B31F-E3A8-49AA-B967-BBB69B7310A3Q36223340-78875751-1921-48C4-A5BE-0841C422CADEQ36351454-F181FB6F-4F54-413C-8FC1-353EC3A4470EQ36675396-2A14BCB4-B306-41CB-9098-0DBE998F7358Q36753242-4595BAFB-C0D0-4D56-B690-7C3B76619023Q37037150-05A57FA4-3ED6-486D-947E-EC0464113262Q37177515-97238FF7-7EED-46E2-B020-D28487DDEA6BQ37283438-76044912-807A-499D-80F8-45BD2CF07F02Q37414937-CB80C54A-3B52-41C2-B3CE-5D7148590EA5Q37554671-EDEF3F69-590E-4A01-9928-3531B31D49C5Q37803236-4C4CCBA0-7EA0-4C1B-BF99-BC1E1D177D1FQ37895459-65E88278-BB15-479A-93B7-B933ACABB4D7Q37942591-00C1F9CB-9424-4B19-88CB-A06827783C44Q40404021-7CA16031-8BB1-430D-9A88-1C2459093482Q43218213-023C9DC5-548B-4A9D-8DB2-6B7E7B1FA458Q45187044-02BF948F-83F7-49D9-A908-8F4F5DC873A2Q50016205-512EB992-4387-4DD0-8585-A0E270F40BB4Q55476982-4E12866D-9B37-4159-9C85-65022679C43E
P2860
Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of r
description
article
@en
im März 2006 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в березні 2006
@uk
name
Cost-effectiveness of screenin ...... study and the prevention of r
@en
Cost-effectiveness of screenin ...... and vascular endstage disease
@nl
type
label
Cost-effectiveness of screenin ...... study and the prevention of r
@en
Cost-effectiveness of screenin ...... and vascular endstage disease
@nl
prefLabel
Cost-effectiveness of screenin ...... study and the prevention of r
@en
Cost-effectiveness of screenin ...... and vascular endstage disease
@nl
P2093
P1476
Cost-effectiveness of screenin ...... ntervention trial (PREVEND IT)
@en
P2093
Cornelis Boersma
Hans L Hillege
Jarir Atthobari
Lolkje T W de Jong-van den Berg
Maarten J Postma
PREVEND IT Study Group
Paul E de Jong
Robin de Vries
Ron T Gansevoort
P304
P356
10.1016/J.CLINTHERA.2006.03.012
P577
2006-03-01T00:00:00Z